2020 Mild Cognitive Impairment (MCI) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Mild Cognitive Impairment (MCI) pipeline report presents a comprehensive overview of the research and development of Mild Cognitive Impairment (MCI) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Two drugs in Research phase, eight drugs in pre-clinical phase, 3 drugs in phase 1, eight drugs in phase 2 and one drug in Phase 3
As of February 2020, the Mild Cognitive Impairment (MCI) pipeline remains robust with 23 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Mild Cognitive Impairment (MCI) treatment. Diverse types of targeted therapies are being explored through clinical trials including Acetylcholinesterase inhibitors; Amyloid beta protein inhibitors; Bcr-abl tyrosine kinase inhibitors; calpain-2 inhibitors; Cannabinoid receptor modulators; CysLT1 antagonist; dopamine and norepinephrine reuptake inhibitor; EIF2AK2 inhibitor; GABA A receptor modulators; Granulocyte-macrophage colony-stimulating factor (GM-CSF or CSF2R); HMG CoA reductase inhibitor; Mas receptor agonist; mgluR2 antagonists; Monoamine oxidase inhibitors; NMDA receptor modulators; Src-Family kinase inhibitors; synaptic vesicle protein (SV2A) protein modulators; Tau protein inhibitors.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Mild Cognitive Impairment (MCI) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Mild Cognitive Impairment (MCI) pipeline drugs profiled in the report include- ABBV-8E12, mGlu2 NAM for Mild Cognitive Impairment, levetiracetam (AGB-101), GABAA Alpha 5 small molecule for Mild cognitive impairment, NYX-458, ladostigil tartrate, gosuranemab (BIIB092), itanapraced (CSP-1103), CST-101, zagotenemab (LY3303560), T-817MA, GRE213, montelukast, calpain-2 inhibitors for Mild Cognitive Impairment, NST-0037, NLS-3 (levofacetoperane), Human immune globulin , sargramostim, bosutinib (SKI-606), PNA6, EIF 2 kinase inhibitor for Mild Cognitive Impairment, brexanolone, THX-130
As of February 2020, the Mild Cognitive Impairment (MCI) pipeline remains robust with 23 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Mild Cognitive Impairment (MCI) treatment. Diverse types of targeted therapies are being explored through clinical trials including Acetylcholinesterase inhibitors; Amyloid beta protein inhibitors; Bcr-abl tyrosine kinase inhibitors; calpain-2 inhibitors; Cannabinoid receptor modulators; CysLT1 antagonist; dopamine and norepinephrine reuptake inhibitor; EIF2AK2 inhibitor; GABA A receptor modulators; Granulocyte-macrophage colony-stimulating factor (GM-CSF or CSF2R); HMG CoA reductase inhibitor; Mas receptor agonist; mgluR2 antagonists; Monoamine oxidase inhibitors; NMDA receptor modulators; Src-Family kinase inhibitors; synaptic vesicle protein (SV2A) protein modulators; Tau protein inhibitors.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Mild Cognitive Impairment (MCI) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Mild Cognitive Impairment (MCI) development
- Mild Cognitive Impairment (MCI) pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Mild Cognitive Impairment (MCI) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Mild Cognitive Impairment (MCI) pipeline candidates included
- Business overview and snapshot of all companies involved in Mild Cognitive Impairment (MCI) pipeline are included
- Latest market and pipeline developments are provided in the report
Mild Cognitive Impairment (MCI) pipeline drugs profiled in the report include- ABBV-8E12, mGlu2 NAM for Mild Cognitive Impairment, levetiracetam (AGB-101), GABAA Alpha 5 small molecule for Mild cognitive impairment, NYX-458, ladostigil tartrate, gosuranemab (BIIB092), itanapraced (CSP-1103), CST-101, zagotenemab (LY3303560), T-817MA, GRE213, montelukast, calpain-2 inhibitors for Mild Cognitive Impairment, NST-0037, NLS-3 (levofacetoperane), Human immune globulin , sargramostim, bosutinib (SKI-606), PNA6, EIF 2 kinase inhibitor for Mild Cognitive Impairment, brexanolone, THX-130
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Mild Cognitive Impairment (MCI) Condition
2.3 Mild Cognitive Impairment (MCI) Pipeline Snapshot, 2020
2.4 Companies investing in Mild Cognitive Impairment (MCI) pipeline therapeutics
2.5 Phase wise Mild Cognitive Impairment (MCI) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Mild Cognitive Impairment (MCI) Pipeline Products
2.7 Route of Administration of Mild Cognitive Impairment (MCI) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 AbbVie Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Addex Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 AgeneBio Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Aptinyx Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Avraham Pharmaceuticals Ltd Overview, Contacts and ASD Pipeline Drugs
3.6 Biogen Inc Overview, Contacts and ASD Pipeline Drugs
3.7 CereSpir Inc Overview, Contacts and ASD Pipeline Drugs
3.8 CuraSen Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Eli Lilly and Co Overview, Contacts and ASD Pipeline Drugs
3.10 Fujifilm Toyama Chemical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.11 Grespo AB Overview, Contacts and ASD Pipeline Drugs
3.12 IntelGenx Corp Overview, Contacts and ASD Pipeline Drugs
3.13 NeurAegis Overview, Contacts and ASD Pipeline Drugs
3.14 Neuron Biopharma SA Overview, Contacts and ASD Pipeline Drugs
3.15 NLS Pharma Group Overview, Contacts and ASD Pipeline Drugs
3.16 Octapharma AG Overview, Contacts and ASD Pipeline Drugs
3.17 Partner Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.18 Pfizer Inc Overview, Contacts and ASD Pipeline Drugs
3.19 ProNeurogen Inc Overview, Contacts and ASD Pipeline Drugs
3.20 Protekt Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.21 Sage Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.22 Therapix Biosciences Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 ABBV-8E12 Drug Details
4.1.1 ABBV-8E12 Current Status
4.1.2 ABBV-8E12 Drug Overview
4.1.3 ABBV-8E12 Mechanism of Action
4.1.4 ABBV-8E12 Licensing/Collaboration Companies
4.1.5 ABBV-8E12 Clinical Trials
4.2 mGlu2 NAM for Mild Cognitive Impairment Drug Details
4.2.1 mGlu2 NAM for Mild Cognitive Impairment Current Status
4.2.2 mGlu2 NAM for Mild Cognitive Impairment Drug Overview
4.2.3 mGlu2 NAM for Mild Cognitive Impairment Mechanism of Action
4.2.4 mGlu2 NAM for Mild Cognitive Impairment Licensing/Collaboration Companies
4.2.5 mGlu2 NAM for Mild Cognitive Impairment Clinical Trials
4.3 levetiracetam (AGB-101) Drug Details
4.3.1 levetiracetam (AGB-101) Current Status
4.3.2 levetiracetam (AGB-101) Drug Overview
4.3.3 levetiracetam (AGB-101) Mechanism of Action
4.3.4 levetiracetam (AGB-101) Licensing/Collaboration Companies
4.3.5 levetiracetam (AGB-101) Clinical Trials
4.4 GABAA Alpha 5 small molecule for Mild cognitive impairment Drug Details
4.4.1 GABAA Alpha 5 small molecule for Mild cognitive impairment Current Status
4.4.2 GABAA Alpha 5 small molecule for Mild cognitive impairment Drug Overview
4.4.3 GABAA Alpha 5 small molecule for Mild cognitive impairment Mechanism of Action
4.4.4 GABAA Alpha 5 small molecule for Mild cognitive impairment Licensing/Collaboration Companies
4.4.5 GABAA Alpha 5 small molecule for Mild cognitive impairment Clinical Trials
4.5 NYX-458 Drug Details
4.5.1 NYX-458 Current Status
4.5.2 NYX-458 Drug Overview
4.5.3 NYX-458 Mechanism of Action
4.5.4 NYX-458 Licensing/Collaboration Companies
4.5.5 NYX-458 Clinical Trials
4.6 ladostigil tartrate Drug Details
4.6.1 ladostigil tartrate Current Status
4.6.2 ladostigil tartrate Drug Overview
4.6.3 ladostigil tartrate Mechanism of Action
4.6.4 ladostigil tartrate Licensing/Collaboration Companies
4.6.5 ladostigil tartrate Clinical Trials
4.7 gosuranemab (BIIB092) Drug Details
4.7.1 gosuranemab (BIIB092) Current Status
4.7.2 gosuranemab (BIIB092) Drug Overview
4.7.3 gosuranemab (BIIB092) Mechanism of Action
4.7.4 gosuranemab (BIIB092) Licensing/Collaboration Companies
4.7.5 gosuranemab (BIIB092) Clinical Trials
4.8 itanapraced (CSP-1103) Drug Details
4.8.1 itanapraced (CSP-1103) Current Status
4.8.2 itanapraced (CSP-1103) Drug Overview
4.8.3 itanapraced (CSP-1103) Mechanism of Action
4.8.4 itanapraced (CSP-1103) Licensing/Collaboration Companies
4.8.5 itanapraced (CSP-1103) Clinical Trials
4.9 CST-101 Drug Details
4.9.1 CST-101 Current Status
4.9.2 CST-101 Drug Overview
4.9.3 CST-101 Mechanism of Action
4.9.4 CST-101 Licensing/Collaboration Companies
4.9.5 CST-101 Clinical Trials
4.10 zagotenemab (LY3303560) Drug Details
4.10.1 zagotenemab (LY3303560) Current Status
4.10.2 zagotenemab (LY3303560) Drug Overview
4.10.3 zagotenemab (LY3303560) Mechanism of Action
4.10.4 zagotenemab (LY3303560) Licensing/Collaboration Companies
4.10.5 zagotenemab (LY3303560) Clinical Trials
4.11 T-817MA Drug Details
4.11.1 T-817MA Current Status
4.11.2 T-817MA Drug Overview
4.11.3 T-817MA Mechanism of Action
4.11.4 T-817MA Licensing/Collaboration Companies
4.11.5 T-817MA Clinical Trials
4.12 GRE213 Drug Details
4.12.1 GRE213 Current Status
4.12.2 GRE213 Drug Overview
4.12.3 GRE213 Mechanism of Action
4.12.4 GRE213 Licensing/Collaboration Companies
4.12.5 GRE213 Clinical Trials
4.13 montelukast Drug Details
4.13.1 montelukast Current Status
4.13.2 montelukast Drug Overview
4.13.3 montelukast Mechanism of Action
4.13.4 montelukast Licensing/Collaboration Companies
4.13.5 montelukast Clinical Trials
4.14 calpain-2 inhibitors for Mild Cognitive Impairment Drug Details
4.14.1 calpain-2 inhibitors for Mild Cognitive Impairment Current Status
4.14.2 calpain-2 inhibitors for Mild Cognitive Impairment Drug Overview
4.14.3 calpain-2 inhibitors for Mild Cognitive Impairment Mechanism of Action
4.14.4 calpain-2 inhibitors for Mild Cognitive Impairment Licensing/Collaboration Companies
4.14.5 calpain-2 inhibitors for Mild Cognitive Impairment Clinical Trials
4.15 NST-0037 Drug Details
4.15.1 NST-0037 Current Status
4.15.2 NST-0037 Drug Overview
4.15.3 NST-0037 Mechanism of Action
4.15.4 NST-0037 Licensing/Collaboration Companies
4.15.5 NST-0037 Clinical Trials
4.16 NLS-3 (levofacetoperane) Drug Details
4.16.1 NLS-3 (levofacetoperane) Current Status
4.16.2 NLS-3 (levofacetoperane) Drug Overview
4.16.3 NLS-3 (levofacetoperane) Mechanism of Action
4.16.4 NLS-3 (levofacetoperane) Licensing/Collaboration Companies
4.16.5 NLS-3 (levofacetoperane) Clinical Trials
4.17 Human immune globulin Drug Details
4.17.1 Human immune globulin Current Status
4.17.2 Human immune globulin Drug Overview
4.17.3 Human immune globulin Mechanism of Action
4.17.4 Human immune globulin Licensing/Collaboration Companies
4.17.5 Human immune globulin Clinical Trials
4.18 sargramostim Drug Details
4.18.1 sargramostim Current Status
4.18.2 sargramostim Drug Overview
4.18.3 sargramostim Mechanism of Action
4.18.4 sargramostim Licensing/Collaboration Companies
4.18.5 sargramostim Clinical Trials
4.19 bosutinib (SKI-606) Drug Details
4.19.1 bosutinib (SKI-606) Current Status
4.19.2 bosutinib (SKI-606) Drug Overview
4.19.3 bosutinib (SKI-606) Mechanism of Action
4.19.4 bosutinib (SKI-606) Licensing/Collaboration Companies
4.19.5 bosutinib (SKI-606) Clinical Trials
4.20 PNA6 Drug Details
4.20.1 PNA6 Current Status
4.20.2 PNA6 Drug Overview
4.20.3 PNA6 Mechanism of Action
4.20.4 PNA6 Licensing/Collaboration Companies
4.20.5 PNA6 Clinical Trials
4.21 EIF 2 kinase inhibitor for Mild Cognitive Impairment Drug Details
4.21.1 EIF 2 kinase inhibitor for Mild Cognitive Impairment Current Status
4.21.2 EIF 2 kinase inhibitor for Mild Cognitive Impairment Drug Overview
4.21.3 EIF 2 kinase inhibitor for Mild Cognitive Impairment Mechanism of Action
4.21.4 EIF 2 kinase inhibitor for Mild Cognitive Impairment Licensing/Collaboration Companies
4.21.5 EIF 2 kinase inhibitor for Mild Cognitive Impairment Clinical Trials
4.22 brexanolone Drug Details
4.22.1 brexanolone Current Status
4.22.2 brexanolone Drug Overview
4.22.3 brexanolone Mechanism of Action
4.22.4 brexanolone Licensing/Collaboration Companies
4.22.5 brexanolone Clinical Trials
4.23 THX-130 Drug Details
4.23.1 THX-130 Current Status
4.23.2 THX-130 Drug Overview
4.23.3 THX-130 Mechanism of Action
4.23.4 THX-130 Licensing/Collaboration Companies
4.23.5 THX-130 Clinical Trials
5. LATEST MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Mild Cognitive Impairment (MCI) Condition
2.3 Mild Cognitive Impairment (MCI) Pipeline Snapshot, 2020
2.4 Companies investing in Mild Cognitive Impairment (MCI) pipeline therapeutics
2.5 Phase wise Mild Cognitive Impairment (MCI) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Mild Cognitive Impairment (MCI) Pipeline Products
2.7 Route of Administration of Mild Cognitive Impairment (MCI) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 AbbVie Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Addex Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 AgeneBio Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Aptinyx Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Avraham Pharmaceuticals Ltd Overview, Contacts and ASD Pipeline Drugs
3.6 Biogen Inc Overview, Contacts and ASD Pipeline Drugs
3.7 CereSpir Inc Overview, Contacts and ASD Pipeline Drugs
3.8 CuraSen Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Eli Lilly and Co Overview, Contacts and ASD Pipeline Drugs
3.10 Fujifilm Toyama Chemical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.11 Grespo AB Overview, Contacts and ASD Pipeline Drugs
3.12 IntelGenx Corp Overview, Contacts and ASD Pipeline Drugs
3.13 NeurAegis Overview, Contacts and ASD Pipeline Drugs
3.14 Neuron Biopharma SA Overview, Contacts and ASD Pipeline Drugs
3.15 NLS Pharma Group Overview, Contacts and ASD Pipeline Drugs
3.16 Octapharma AG Overview, Contacts and ASD Pipeline Drugs
3.17 Partner Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.18 Pfizer Inc Overview, Contacts and ASD Pipeline Drugs
3.19 ProNeurogen Inc Overview, Contacts and ASD Pipeline Drugs
3.20 Protekt Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.21 Sage Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.22 Therapix Biosciences Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 ABBV-8E12 Drug Details
4.1.1 ABBV-8E12 Current Status
4.1.2 ABBV-8E12 Drug Overview
4.1.3 ABBV-8E12 Mechanism of Action
4.1.4 ABBV-8E12 Licensing/Collaboration Companies
4.1.5 ABBV-8E12 Clinical Trials
4.2 mGlu2 NAM for Mild Cognitive Impairment Drug Details
4.2.1 mGlu2 NAM for Mild Cognitive Impairment Current Status
4.2.2 mGlu2 NAM for Mild Cognitive Impairment Drug Overview
4.2.3 mGlu2 NAM for Mild Cognitive Impairment Mechanism of Action
4.2.4 mGlu2 NAM for Mild Cognitive Impairment Licensing/Collaboration Companies
4.2.5 mGlu2 NAM for Mild Cognitive Impairment Clinical Trials
4.3 levetiracetam (AGB-101) Drug Details
4.3.1 levetiracetam (AGB-101) Current Status
4.3.2 levetiracetam (AGB-101) Drug Overview
4.3.3 levetiracetam (AGB-101) Mechanism of Action
4.3.4 levetiracetam (AGB-101) Licensing/Collaboration Companies
4.3.5 levetiracetam (AGB-101) Clinical Trials
4.4 GABAA Alpha 5 small molecule for Mild cognitive impairment Drug Details
4.4.1 GABAA Alpha 5 small molecule for Mild cognitive impairment Current Status
4.4.2 GABAA Alpha 5 small molecule for Mild cognitive impairment Drug Overview
4.4.3 GABAA Alpha 5 small molecule for Mild cognitive impairment Mechanism of Action
4.4.4 GABAA Alpha 5 small molecule for Mild cognitive impairment Licensing/Collaboration Companies
4.4.5 GABAA Alpha 5 small molecule for Mild cognitive impairment Clinical Trials
4.5 NYX-458 Drug Details
4.5.1 NYX-458 Current Status
4.5.2 NYX-458 Drug Overview
4.5.3 NYX-458 Mechanism of Action
4.5.4 NYX-458 Licensing/Collaboration Companies
4.5.5 NYX-458 Clinical Trials
4.6 ladostigil tartrate Drug Details
4.6.1 ladostigil tartrate Current Status
4.6.2 ladostigil tartrate Drug Overview
4.6.3 ladostigil tartrate Mechanism of Action
4.6.4 ladostigil tartrate Licensing/Collaboration Companies
4.6.5 ladostigil tartrate Clinical Trials
4.7 gosuranemab (BIIB092) Drug Details
4.7.1 gosuranemab (BIIB092) Current Status
4.7.2 gosuranemab (BIIB092) Drug Overview
4.7.3 gosuranemab (BIIB092) Mechanism of Action
4.7.4 gosuranemab (BIIB092) Licensing/Collaboration Companies
4.7.5 gosuranemab (BIIB092) Clinical Trials
4.8 itanapraced (CSP-1103) Drug Details
4.8.1 itanapraced (CSP-1103) Current Status
4.8.2 itanapraced (CSP-1103) Drug Overview
4.8.3 itanapraced (CSP-1103) Mechanism of Action
4.8.4 itanapraced (CSP-1103) Licensing/Collaboration Companies
4.8.5 itanapraced (CSP-1103) Clinical Trials
4.9 CST-101 Drug Details
4.9.1 CST-101 Current Status
4.9.2 CST-101 Drug Overview
4.9.3 CST-101 Mechanism of Action
4.9.4 CST-101 Licensing/Collaboration Companies
4.9.5 CST-101 Clinical Trials
4.10 zagotenemab (LY3303560) Drug Details
4.10.1 zagotenemab (LY3303560) Current Status
4.10.2 zagotenemab (LY3303560) Drug Overview
4.10.3 zagotenemab (LY3303560) Mechanism of Action
4.10.4 zagotenemab (LY3303560) Licensing/Collaboration Companies
4.10.5 zagotenemab (LY3303560) Clinical Trials
4.11 T-817MA Drug Details
4.11.1 T-817MA Current Status
4.11.2 T-817MA Drug Overview
4.11.3 T-817MA Mechanism of Action
4.11.4 T-817MA Licensing/Collaboration Companies
4.11.5 T-817MA Clinical Trials
4.12 GRE213 Drug Details
4.12.1 GRE213 Current Status
4.12.2 GRE213 Drug Overview
4.12.3 GRE213 Mechanism of Action
4.12.4 GRE213 Licensing/Collaboration Companies
4.12.5 GRE213 Clinical Trials
4.13 montelukast Drug Details
4.13.1 montelukast Current Status
4.13.2 montelukast Drug Overview
4.13.3 montelukast Mechanism of Action
4.13.4 montelukast Licensing/Collaboration Companies
4.13.5 montelukast Clinical Trials
4.14 calpain-2 inhibitors for Mild Cognitive Impairment Drug Details
4.14.1 calpain-2 inhibitors for Mild Cognitive Impairment Current Status
4.14.2 calpain-2 inhibitors for Mild Cognitive Impairment Drug Overview
4.14.3 calpain-2 inhibitors for Mild Cognitive Impairment Mechanism of Action
4.14.4 calpain-2 inhibitors for Mild Cognitive Impairment Licensing/Collaboration Companies
4.14.5 calpain-2 inhibitors for Mild Cognitive Impairment Clinical Trials
4.15 NST-0037 Drug Details
4.15.1 NST-0037 Current Status
4.15.2 NST-0037 Drug Overview
4.15.3 NST-0037 Mechanism of Action
4.15.4 NST-0037 Licensing/Collaboration Companies
4.15.5 NST-0037 Clinical Trials
4.16 NLS-3 (levofacetoperane) Drug Details
4.16.1 NLS-3 (levofacetoperane) Current Status
4.16.2 NLS-3 (levofacetoperane) Drug Overview
4.16.3 NLS-3 (levofacetoperane) Mechanism of Action
4.16.4 NLS-3 (levofacetoperane) Licensing/Collaboration Companies
4.16.5 NLS-3 (levofacetoperane) Clinical Trials
4.17 Human immune globulin Drug Details
4.17.1 Human immune globulin Current Status
4.17.2 Human immune globulin Drug Overview
4.17.3 Human immune globulin Mechanism of Action
4.17.4 Human immune globulin Licensing/Collaboration Companies
4.17.5 Human immune globulin Clinical Trials
4.18 sargramostim Drug Details
4.18.1 sargramostim Current Status
4.18.2 sargramostim Drug Overview
4.18.3 sargramostim Mechanism of Action
4.18.4 sargramostim Licensing/Collaboration Companies
4.18.5 sargramostim Clinical Trials
4.19 bosutinib (SKI-606) Drug Details
4.19.1 bosutinib (SKI-606) Current Status
4.19.2 bosutinib (SKI-606) Drug Overview
4.19.3 bosutinib (SKI-606) Mechanism of Action
4.19.4 bosutinib (SKI-606) Licensing/Collaboration Companies
4.19.5 bosutinib (SKI-606) Clinical Trials
4.20 PNA6 Drug Details
4.20.1 PNA6 Current Status
4.20.2 PNA6 Drug Overview
4.20.3 PNA6 Mechanism of Action
4.20.4 PNA6 Licensing/Collaboration Companies
4.20.5 PNA6 Clinical Trials
4.21 EIF 2 kinase inhibitor for Mild Cognitive Impairment Drug Details
4.21.1 EIF 2 kinase inhibitor for Mild Cognitive Impairment Current Status
4.21.2 EIF 2 kinase inhibitor for Mild Cognitive Impairment Drug Overview
4.21.3 EIF 2 kinase inhibitor for Mild Cognitive Impairment Mechanism of Action
4.21.4 EIF 2 kinase inhibitor for Mild Cognitive Impairment Licensing/Collaboration Companies
4.21.5 EIF 2 kinase inhibitor for Mild Cognitive Impairment Clinical Trials
4.22 brexanolone Drug Details
4.22.1 brexanolone Current Status
4.22.2 brexanolone Drug Overview
4.22.3 brexanolone Mechanism of Action
4.22.4 brexanolone Licensing/Collaboration Companies
4.22.5 brexanolone Clinical Trials
4.23 THX-130 Drug Details
4.23.1 THX-130 Current Status
4.23.2 THX-130 Drug Overview
4.23.3 THX-130 Mechanism of Action
4.23.4 THX-130 Licensing/Collaboration Companies
4.23.5 THX-130 Clinical Trials
5. LATEST MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
